This application addresses broad area (03) - Biomarkers Discovery and Validation and the specific challenge topic, 03-HL-101: Identify and validate clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction. Project Title: Osteopontin: a Novel Biomarker for Calcific Aortic Valve Diseases The calcification of the Aortic Valve represents a multifactorial process with varied underlying associated pathologies. Despite the high prevalence and mortality associated with aortic valve calcification, little is known about its pathogenetic mechanisms. We propose a two-year translational research study to validate and characterize blood- and tissue- derived Osteopontin as a biomarker of valvular calcification. Osteopontin (OPN) is a multifunctional glyco-phospho-protein implicated in the regulation of both physiological calcification and biomineralization of dystrophic and ectopic sites. Surprisingly, although OPN inhibits calcification both in vitro and in vivo, elevated levels of OPN have been found in the heart valves of patients with calcified valvular disease. All available studies have been limited to the quantitative assessment of OPN during valvular calcification. Upon informed consent, blood and tissue specimens will be collected from patients with signs of Calcific Aortic Valve Disease and from age- and gender-match controls. Osteopontin protein and RNA will be purified. The characterization of post-translational modification(s) of isolated OPN and/or the different Opn splicing variants may provide insight to the functional role(s) of OPN in the pathogenesis of Aortic Valve Calcification. Such insights can be used to develop predictor(s) for the degree and progression of valvular calcification and to identify potential therapeutic targets for this prevalent and significant disease.

Public Health Relevance

The characterization of the biological activity of circulating and valve-associated OPN from patients with calcific aortic valve stenosis has never been performed. The study we propose can bring a significant contribution to the identification of therapeutic targets that will benefit patients not only with Calcific Aortic Valve Diseases but also with other pathologies leading to structural degeneration of aortic valve tissue. The study will also provide an immediate economic benefit to the region with the direct creation on new jobs and the direct and indirect retain of others. Public Health Relevance: The calcification of the aortic valve represents a multifactor process underling varied associated pathologies. Due to the high prevalence and mortality associated with aortic valve calcification novel biomarkers are constantly needed for an early diagnosis of the disease. We propose a translational research study aim to characterize tissue- and blood-derived osteopontin as a predictor for the degree and progression of aortic valve calcification

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
NIH Challenge Grants and Partnerships Program (RC1)
Project #
5RC1HL100035-02
Application #
7934550
Study Section
Special Emphasis Panel (ZRG1-CVRS-B (58))
Program Officer
Evans, Frank
Project Start
2009-09-30
Project End
2012-02-29
Budget Start
2010-09-01
Budget End
2012-02-29
Support Year
2
Fiscal Year
2010
Total Cost
$499,969
Indirect Cost
Name
University of Pennsylvania
Department
Surgery
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Poggio, Paolo; Sainger, Rachana; Branchetti, Emanuela et al. (2013) Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis. Cardiovasc Res 98:402-10
Branchetti, Emanuela; Sainger, Rachana; Poggio, Paolo et al. (2013) Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis. Arterioscler Thromb Vasc Biol 33:e66-74
Sainger, Rachana; Grau, Juan B; Branchetti, Emanuela et al. (2013) Comparison of transesophageal echocardiographic analysis and circulating biomarker expression profile in calcific aortic valve disease. J Heart Valve Dis 22:156-65
Grau, Juan B; Poggio, Paolo; Sainger, Rachana et al. (2012) Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg 93:79-86
Zapolanski, Alex; Mak, Andrew W C; Ferrari, Giovanni et al. (2012) Impact of New York Heart Association classification, advanced age and patient-prosthesis mismatch on outcomes in aortic valve replacement surgery. Interact Cardiovasc Thorac Surg 15:371-6
Sainger, Rachana; Grau, Juan B; Poggio, Paolo et al. (2012) Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers 17:111-8
Sainger, Rachana; Grau, Juan B; Branchetti, Emanuela et al. (2012) Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation. J Cell Physiol 227:2595-604
Poggio, Paolo; Grau, Juan B; Field, Benjamin C et al. (2011) Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J Cell Physiol 226:2139-49
Beckmann, Erik; Grau, Juan B; Sainger, Rachana et al. (2010) Insights into the use of biomarkers in calcific aortic valve disease. J Heart Valve Dis 19:441-52
Ferrari, Giovanni; Sainger, Rachana; Beckmann, Erik et al. (2010) Validation of plasma biomarkers in degenerative calcific aortic stenosis. J Surg Res 163:12-7

Showing the most recent 10 out of 11 publications